Medtronic PLC $MDT Shares Purchased by JB Capital LLC

JB Capital LLC boosted its holdings in Medtronic PLC (NYSE:MDT) by 8.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 137,615 shares of the medical technology company’s stock after buying an additional 10,152 shares during the period. JB Capital LLC’s holdings in Medtronic were worth $13,106,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. 1248 Management LLC purchased a new position in shares of Medtronic in the 1st quarter valued at $26,000. Delos Wealth Advisors LLC acquired a new stake in Medtronic in the 2nd quarter valued at $27,000. Twin Tree Management LP acquired a new position in shares of Medtronic during the first quarter worth about $29,000. Tripletail Wealth Management LLC purchased a new stake in shares of Medtronic in the third quarter worth about $34,000. Finally, GFG Capital LLC acquired a new stake in shares of Medtronic in the second quarter valued at about $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Stock Up 0.5%

Shares of NYSE:MDT opened at $96.68 on Wednesday. The firm has a market cap of $123.94 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 2.53 and a beta of 0.71. The company has a fifty day simple moving average of $97.56 and a 200 day simple moving average of $93.92. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.38 and a 12-month high of $106.33.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. The firm’s revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.26 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities research analysts anticipate that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 16th. Investors of record on Friday, December 26th will be paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, December 26th. Medtronic’s dividend payout ratio (DPR) is 76.55%.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday, November 19th. Truist Financial dropped their price objective on shares of Medtronic from $110.00 to $107.00 and set a “hold” rating on the stock in a research note on Thursday, December 18th. Stifel Nicolaus upped their target price on shares of Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Sanford C. Bernstein set a $111.00 price target on shares of Medtronic in a report on Wednesday, November 19th. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Medtronic in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and twelve have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $109.94.

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter?defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).